Aug 22, 2017, 08:22 ET
BURLINGTON, Mass., Aug. 22, 2017 /PRNewswire/ -- Decision Resources Group finds that the gastroesophageal cancer market will grow significantly from almost $2 billion in 2016 to $13 billion in 2026, making it one of the fastest growing oncology indications. Fueling this robust growth will be the approval of multiple novel premium-priced biologics, namely PD-1/PD-L1 inhibitors.
Learn more about the full report here: http://bit.ly/2x5x3sq
Other key findings from the Disease Landscape & Forecast report entitled Gastroesophageal Cancer:
- Gastric cancer vs. esophageal cancer: The gastric and GEJ adenocarcinoma market will account for three-quarters of the total gastroesophageal market in 2026. This is largely attributable to the high incidence of gastric and GEJ adenocarcinoma in Japan.
- Growth of the market in Japan: Gastroesophageal cancer sales in Japan will increase from $1 billion in 2016 to over $6 billion in 2026; this region will account for half of total sales in 2026.
- New market entrants for first-line HER2-negative gastric and GEJ adenocarcinoma: By 2026, this will become a dynamic space with multiple agents jostling for patient share; Bristol-Myers Squibb/Ono Pharmaceutical's Opdivo with or without Yervoy , Merck & Co.'s Keytruda (pembrolizumab), Merck KGaA/Pfizer's Bavencio and Gilead Science's matrix metalloproteinase-9 inhibitor, andecaliximab.
- Immune checkpoint inhibitors will drive sales in gastroesophageal cancer: The emergence of immune checkpoint inhibitors, particularly PD-1 inhibitors (i.e., Opdivo and Keytruda) during the first half of our forecast period, will drive considerable growth in sales through 2026. This is compounded by the expected approval of Bavencio as the only first-line maintenance treatment for gastric and GEJ adenocarcinoma.
Comments from Decision Resources Group Analyst Paul Wilcock Ph.D.:
- "This is an exciting time in esophageal cancer, with the expected approval of Keytruda as a second-line treatment in 2019—the first noncytotoxic agent to be approved in this indication. Hopefully this will pave the way for multiple label expansions for Keytruda, as well as the approval of Opdivo with or without Yervoy or chemotherapy. The outlook for esophageal cancer patients is likely to significantly improve over the forecast period."
- "Despite the expected approval of more efficacious, better-tolerated agents across many of the gastroesophageal cancer populations over the forecast period, we expect some unmet needs will persist. For example, the urgent need for a selection of more efficacious drug treatment options for resectable disease, and the need for a range of drug classes aside from PD-1/CTLA-4 inhibitors and cytotoxic agents in esophageal cancer will likely remain in 2026."
About Decision Resources Group
DRG, a subsidiary of Piramal Enterprises Ltd., is the premier source for global healthcare data and market intelligence. A trusted partner for over 20 years, DRG helps companies competing in the global healthcare industry make informed business decisions. Organizations committed to the developing and delivering life-changing therapies to patients rely on DRG's in-house team of expert healthcare analysts, data scientists, and consultants for critical guidance. DRG products and services, built on extensive data assets and delivered by experts, empower organizations to succeed in complex healthcare markets.
Decision Resources Group
SOURCE Decision Resources Group
Share this article